May 1 (UPI) --Pharmaceutical giant Johnson & Johnson on Wednesday said it is taking steps to resolve a multibillion dollar, cancer-related lawsuit with thousands of individuals over claims that ...
J&J will buy Momenta Pharmaceuticals for roughly $6.5 billion in cash, paving the way for its Janssen unit to expand its efforts into autoimmune disease treatments. J&J will pay $52.50 for each ...
Johnson and Johnson reiterated in its statement on Wednesday, May 1, that “none of the talc-related claims against it have merit” getty Stock image of baby powder Johnson & Johnson has offered to pay ...
Benzinga - by Vandana Singh, Benzinga Editor. Wednesday, Johnson & Johnson (NYSE:JNJ) announced its intention to proceed with a $6.475 billion settlement to resolve numerous lawsuits related to ...
Wednesday's proposed plan immediately got pushback from lawyers representing ovarian cancer victims: "This is not a done deal," Beasley Allen's Andy Birchfield told Law.com. "There is substantial ...
Johnson & Johnson topped the Street's Q4 earnings forecast, but fell modestly shy on revenues even as it sees Covid vaccine sales rising to $3.5 billion this year. Johnson & Johnson (JNJ ...
Johnson and Johnson revealed lower earnings and sales numbers than expected in Q4 2022 Even before Q4 numbers were released, JNJ started falling after a slew of new stories hit the press Even ...
Investing in J&J offers potential dividend income with 61 years of consecutive increases. J&J plans to spin off its consumer division, focusing on pharmaceuticals and medical technology.
, opens new tab said on Thursday it would acquire Proteologix for $850 million in cash, as it looks to gain access to the privately held company's experimental atopic dermatitis treatments.
Dallas Mayor Eric Johnson wants a City Council committee to meet as soon as possible to consider opposing severance pay for former city manager T.C. Broadnax. Johnson in a memo Thursday to Mayor ...
Johnson & Johnson said it would acquire Proteologix for $850 million as it looks to gain access to the privately held company’s experimental atopic dermatitis treatments. Proteologix’s ...